About Acticor Biotech
Acticor Biotech is a company based in Paris (France) founded in 2013. Acticor Biotech has raised $31.36 million across 7 funding rounds from investors including Bpifrance, GO CAPITAL and Anaxago. Acticor Biotech offers products and services including Glenzocimab. Acticor Biotech operates in a competitive market with competitors including Alexion, argenx, BigHat, Kodiak Sciences and Visterra, among others.
- Headquarter Paris, France
- Stage Public
- SectorsHealthcare
- Website acticor-biotech.com
- Social LinkedIn X
- Legal Name Acticor Biotech Sa
- Total Equity Funding$31.36M (USD)
in 7 rounds
- Latest Funding Round$7.77M (USD), Series B
Nov 2019
- InvestorsBpifrance
& 6 more
Products & Services of Acticor Biotech
Acticor Biotech offers a comprehensive portfolio of products and services, including Glenzocimab.
Drug for treating acute ischemic stroke and cardiovascular emergencies.
Funding Insights of Acticor Biotech
Acticor Biotech has successfully raised a total of $31.36M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $7.77 million completed in November 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $31.36M
- Total Rounds 7
- Last Round Series B — $7.77M
- First Round $661,030
(Jan 2015)
- Investors Count 7
All 7 funding rounds of Acticor Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2019 | $7.77M | Series B | – | GO CAPITAL | |
| Oct 2018 | $17.72M | Series B | – | Newton Biocapital | |
| Jan 2018 | $2.05M | Series B | – | Primer Capital | |
| Jan 2018 | $2.65M | Grant | – | – | |
| Feb 2017 | $1.61M | Series B | – | Karista | – |
| Jul 2016 | $1.55M | Seed | – | – | – |
| Jan 2015 | $661,030 | Seed | – | – | – |
7 investors in total: 7 institutional.
Investors in Acticor Biotech
Acticor Biotech has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Bpifrance, GO CAPITAL and Anaxago.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are directed toward multiple sectors. | 2003 | gocapital.fr | Rennes, France | |
Investments are focused on life sciences in Europe and Japan. | – | newtonbiocapital.com | Brussels, Belgium | |
Karista is recognized as an early-stage venture capital firm. | 2001 | karista.vc | Paris, France | |
Venture capital investment firm based out of South Korea | – | venture.miraeasset.com | Seoul, South Korea | |
- | – | primer-capital.com | - | |
Equity crowdfunding is facilitated for innovative projects and companies. | 2012 | anaxago.com | Paris, France | |
Corporate consultancy, advisory, and funding services are provided to businesses. | 2012 | bpifrance.com | Maisons Alfort, France |
Investor details for Acticor Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Acticor Biotech
27 people are tracked at Acticor Biotech (7 in leadership, 7 in board & advisors, 13 in team).
| Name | Role | Group |
|---|---|---|
Gilles Avenard | CEO | Leadership |
Yannick Plétan | Chief Medical Officer & General Manager | Leadership |
Kristell Lebozec | Head of Pharmaceutical Development | Leadership |
Anouar Sari | Head of Clinical Operations | Leadership |
Sophie Binay | General Manager & Chief Scientific Officer | Leadership |
Violaine Desort-Hénin | Director of Medical Operations | Leadership |
Sirine Bougamra | Medical Director | Leadership |
Guy Heynen | Board Member | Board & advisors |
Catherine Boule | Board Member | Board & advisors |
Leila Nicolas | Board Member | Board & advisors |
Alain Munoz | Chairman | Board & advisors |
Rinaldo Del Bono | Board Member | Board & advisors |
Martine Jandrot-Perrus | Scientific Founder | Board & advisors |
Jean-Pierre Cazenave | Board Member | Board & advisors |
Bérengère Hennebelle | CMC & Non-Clinical Regulatory Affairs Senior Manager | Team |
Marion Galaup | Analytical Development Project Manager | Team |
Véronia Safwat | Clinical Trial Manager | Team |
Sandra Lourenço-Lopes | Office Manager | Team |
Marilyn Labart | Senior Clinical Project Manager | Team |
Chloé Zulian | Clinical Project Manager | Team |
7 more people are available in the full profile.
Complete people profiles for Acticor Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Acticor Biotech
4 dated milestones of Acticor Biotech across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Acticor Biotech is founded.
- Funding First funding round of $661K.
- Funding Latest funding round, Series B, of $7.8M.
- IPO Lists on the stock exchange (IPO).
Competitors of Acticor Biotech
Acticor Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alexion, argenx, BigHat, Kodiak Sciences and Visterra, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alexion.com | 1992 | Zurich, Switzerland | $8M | 1 | Therapies for rare and devastating diseases are developed by Alexion. | |
| argenx.com | 2008 | Ghent, Belgium | $61.9M | 355 | Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | |
| bighatbio.com | 2019 | San Carlos, United States | $148.41M | – | Antibody therapies are developed through machine learning and synthetic biology. | |
| kodiak.com | 2009 | Palo Alto, United States | $35.84M | 112 | Therapeutics for retinal diseases are developed by the company. | |
| visterrainc.com | 2007 | Cambridge, United States | $116.17M | 79 | Developer of monoclonal antibodies against infectious diseases | |
| scholarrock.com | 2012 | Cambridge, United States | $103.3M | 150 | Antibody-based drugs for primary myopathies are developed and targeted. | |
| alentis.ch | 2019 | Basel, Switzerland | $365.66M | – | Therapies for fibrosis, cirrhosis, and liver cancer are developed. | |
| affibody.se | 1998 | Solna, Sweden | $43.28M | – | Developer of antibody mimetic and protein based drug for the treatment of multiple diseases | |
| macrogenics.com | 2000 | Rockville, United States | $126.02M | 339 | A biopharmaceutical company focused on cancer therapeutics development. | |
| iggenix.com | 2019 | San Francisco, United States | $75M | – | Therapeutic solutions for food allergies are developed via antibody platforms. |
Detailed competitors of Acticor Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Acticor Biotech
Complete news archive for Acticor Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Acticor Biotech
10 companies that operate in the same segment as Acticor Biotech (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Acticor Biotech
Acticor Biotech was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Acticor Biotech is headquartered in Paris, France.
Gilles Avenard is the current CEO of Acticor Biotech.
Acticor Biotech is a funded company, having raised a total of $31.36M across 7 funding rounds to date. The company's 1st funding round was a Seed of $661.03K, raised on Jan 2015.
Acticor Biotech was founded in 2013 in Paris, France, within the biotechnology sector. Therapeutic monoclonal antibodies are developed by the company for ischemic stroke treatment. Focus is placed on ACT-017, a humanized antibody targeting platelet glycoprotein VI in cerebral stroke cases. Operations center on advancing these immunotherapeutics through research and development processes.
Acticor Biotech's top competitors include argenx, Kodiak Sciences and MacroGenics.
Acticor Biotech offers Glenzocimab.
Acticor Biotech has 7 investors. Key investors include Bpifrance, GO CAPITAL, Anaxago, Newton Biocapital, and Karista.
Acticor Biotech operates through Acticor Biotech Sa.